Fibroadenoma is the most common benign breast tumor in women under 30 years. This study aimed to contribute to the knowledge of the genetic factors involved in the occurrence and progression of mammary fibroadenomas. MED12 and CYP17A1 were sequenced in fibroadenomas and blood in 43 Senegalese women. The Alamut-visual software, which includes the pathogenicity prediction software SIFT, Polyphen2 and MutationTaster, was used to search for mutations. DnaSP version 5.10.01, MEGA version 7.0.14 and Arlequin version 3.5.1.3 were used to determine phylogenetic parameters including indices of genetic variability and diversity and genetic differentiation parameters. A deletion in the poly-A tail of MED12 was identified in our study population. An alteration of Methionine (M1) was observed on exon 1 of CYP17A1. Our results also show that most of the variants found on exon 2 of MED12 and exon 1 of CYP17A1 have the probability of causing the appearance of breast fibroadenomas according by the three pathogenicity prediction software. We found 23 new variants on the MED12 gene and 109 new variants on the CYP17A1 gene. The amino acid frequency distribution between blood and fibroadenomas shows a statistically significant difference in Glycine, Arginine and Valine for MED12 and Cysteine, Phenylalanine, Histidine, Asparagine, Arginine, Tryptophan and Tyrosine for CYP17A1. In addition the selection test shows that codon 20 of exon 1 of CYP17A1 which codes for Arginine (p.20Arg) is under positive selection in mammary fibroadenomas. Genetic differentiation parameters show a clear difference between blood and breast fibroadenomas. These results show for the first time the involvement of the CYP17A1 gene in breast fibroadenomas and confirm the involvement of MED12. Codon 20 of exon 1 of CYP17A1 being under positive selection could be used as a biomarker in breast fibroadenomas.
| Published in | International Journal of Genetics and Genomics (Volume 8, Issue 2) |
| DOI | 10.11648/j.ijgg.20200802.13 |
| Page(s) | 66-77 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
Fibroadenoma, Benign, Mammary, Breast, MED12, CYP17A1, Arginine, Codon 20
| [1] | Lee M. and Soltanian H. T. (2015). Breast fibroadenomas in adolescents: current perspectives. Dove Press: Adolescent Health Medecine and Therapeutics. 6. 159-163. DOI: 10.2147/AHMT.S55833. |
| [2] | Alagar S. R. and Purushothaman R. (2015). An analytical study on fibroadenoma of the breast: ESIC Medical College and hospital, Coimbatore, Tamilnadu, India. CIBTech Journal of Surgery. 4 (2). 40-45. |
| [3] | Shaik A. N., Ruterbusch J. J., Abdulfatah E., Daaboul M. H. D. F., Pardeshi V., Visscher D. W., Bandyopadhway S., Ali-Fehmi R. and Cote M. L. (2018). Breast fibroadenomas are not associated with increased breast cancer risk in an African American contemporary cohort of women with benign breast disease. Breast Cancer Research. 20 (1). 91p. DOI: 10.1186/s13058-018-1027-6. |
| [4] | Ihekwaba F. N. (1994). Benign breast disease in Nigerian Women: a study of 657 patients. Journal of the Royal College of Surgeons of Edinburgh. 39 (5). 280-283. |
| [5] | Gueye S. M. K., Gueye M., Coulibaly M. T., Mahtouk D. et Moreau J. C. (2017). Tumeurs bénignes du sein à l’unité de sénologie du Centre Hospitalier Universitaire Aristide Le Dantec de Dakar (Sénégal). The Pan African Medical Journal. (27). 251. DOI: 10.11604/pamj.2017.27.251.12262. |
| [6] | Oluwole S. F. and Freeman H. P. (1979). Analysis of Benign Breast Lesions in Blacks. The American Journal of Surgery. 137. 786-789. |
| [7] | Klinger K., Bhimani C., Shames J. and Sevrukov A. (2019). Fibroadenoma: From Imaging Evaluation to Treatment. Journal American Osteopathic College Radiology. 8 (2). |
| [8] | Hefler L. A., Tempfer C. B., Grimm C., Lebrecht A., Ulbrich E., Heinze G., Leodolter S., Schneeberger C., Manfred W. Mueller M. W., Muendlein A. and, Koelbl H. (2004). Estrogen-Metabolizing Gene Polymorphisms in the Assessment of Breast Carcinoma Risk and Fibroadenoma Risk in Caucasian Women. Cancer 101 (2): 264-269. |
| [9] | Interaction biosoftware a SOPHiA GENETICS company. ALAMUT VISUAL. Available on: https://www.interactive-biosoftware.com/alamut-visual/ |
| [10] | Sherry S. T., Ward M. H., Kholodov M., Baker J., Phan L., Smigielski E. M. and Sirotkin, K. (2001). dbSNP: the NCBI database of genetic variation. Nucleic acids research, 29 (1), 308–311. DOI: 10.1093/nar/29.1.308. |
| [11] | Landrum M., Lee J. M., Riley G. R., Jang W., Rubinstein W. S., Church D. M. and Maglott D. R. (2014). ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Research. 42 (Database issue). D980-D985. |
| [12] | Sim N-L., Kumar P., Hu J., Henikoff S., Schneider G. and Ng P. C. (2012). SIFT Web Server: Predicting Effects of Amino Acid Substitutions on Proteins ». Nucleic Acids Research. 40 (W1). W452-457. |
| [13] | Adzhubei I., Jordan D. M., and Sunyaev S. R. (2013). Predicting Functional Effect of Human Missense Mutations Using Polyphen-2. Current Protocols in Human Genetics. Chapter7. 7.20.1-7.20.41. |
| [14] | Schwarz J. M., Cooper D. N., Schuelke M. and Seelow D. (2014). MutationTaster2: Mutation Prediction for the Deep-Sequencing Age. Nature Methods. 11 (4). 361-362. |
| [15] | Hall T. A. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. Symp. 41. 95-98. |
| [16] | Thompson T. D., Higgins D. G. and Gibson T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22. 4673-4680. |
| [17] | Rozas J., Librado P., Sanchez-Del Barrio J. C., Messeguer X. and Rozas R. (2010). DnaSP version 5 Help Contents [Help File]. http://www.ub.edu/dnasp/ |
| [18] | Kumar S., Stecher G and Tamura K. (2015). MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Molecular Biology and Evolution. |
| [19] | RStudio Team. (2017). RStudio: Integrated Development Environment for R. Boston, MA. RStudio, Inc. Available on: http://www.rstudio.com/. |
| [20] | Excoffier L., Laval G. and Schneider S. (2010). Arlequin ver.3.1: An integrated software package for population genetics data analysis. Evol. Bioinform. Online. 1. 45-50. |
| [21] | Kénémé B., Mbaye F., Ka S., Diop B., Dem A. and Sembène M. (2017). Mediator Complex Subunit 12 Gene Polymorphisms in Uterine Fibroids and Breast Fibroadenomas in Senegalese Women. International Biological Biomedical Journal. 3 (1). 8-16. |
| [22] | Makinen N., Mehine M., Tolvanen J., Kaasinen E., Li Y., Lehtonen H. J., Gentile M., Yan J., Enge M., Taipale M., Aavikko M., Katainen R., Virolainen E., Böhling T., Koski T. A., Launonen V., Sjöberg J., Taipale J., Vahterista P. and Aaltonen L. A. (2011). MED12 the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas. Science. 334 (6053). 252-255. |
| [23] | Halder S. K., Laknaur A., Miller J., Layman L. C., Diamond M. and Al-Hendy A. (2015). Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol. Genet. Genomics. 290. 505–511. DOI: 10.1007/s00438-014-0938-x. |
| [24] | Bourbon H-M. (2008). Comparative genomics supports a deep evolutionary origin for the large, four-module transcriptional mediator complex. Nucleic Acids Research. 36 (12). 3993-4008. DOI: 10.1093/nar/gkn349. |
| [25] | Turunen M., Spaeth J. M., Keskitalo S., Park M. J., Kivioja T., Clark A. D., Mäkinen N., Gao F., Palin K., Nurkkala H., Vähärautio A., Aavikko M., Kämpjärvi K., Vahteristo P., Kim C. A., Aaltonen L. A., Varjosalo M., Taipale J. and Boyer T. G. (2014). Uterine leiomyoma-linked MED12 mutations disrupt mediator associated CDK activity. Cell Reports. 7 (3). 654-660. DOI: 10.1016/j.celrep.2014.03.047. |
| [26] | Carey A. H., Waterworth D., Patel K., White D., Little J., Novelli P. Franks S. and Williamson R. (1994). Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Molecular Genetics. 3 (10). 1873-1876. DOI: 10.1093/hmg/3.10.1873. |
| [27] | Sharp L. Cardy A. H. Cotton S. C. and Little J. (2004). CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. A HuGE review. American Journal of Epidemiology. 160 (8). 729-740. DOI: 10.1093/aje/kwh287. |
| [28] | Sata F., Yamada H., Yamada A., Kato E. H., Kataoka S. Saijo Y., Kondo T., Tamaki J., Minakami H. and Kishi R. (2003). A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss. Molecular Human Reproduction. 9 (11). 725-728. DOI: https://doi.org/10.1093/molehr/gag089 |
| [29] | Li T. C., Tuckerman E. M. and Laird S. M. (2002). Endometrial factors in recurrent miscarriage. Human Reproduction Update. 8 (1). 43-52. DOI: https://doi.org/10.1093/humupd/8.1.43. |
| [30] | Sun J., Zhang H. Gao M., Tang Z., Guo D., Zhang X., Li R. Liu Y. Sun W. and Sun X. (2017). Association between CYP17 T-34C rs743572 and breast cancer risk. Oncotarget. 9 (3). 4200-4213. DOI: 10.18632/oncotarget.23688. |
| [31] | Kaur R., Kaur T. and Kaur A. (2018). Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics. 35 (6). 1123-1129. |
| [32] | Suzuki Y., Nagashima T., Nomura Y., Onigata K., Nagashima, K. and Morikawa A. (1998). A New Compound Heterozygous Mutation (W17X, 436 + 5GT) in the Cytochrome P450c17 Gene Causes 17 Alpha-Hydroxylase/17,20-Lyase Deficiency. The Journal of Clinical Endocrinology and Metabolism 83 (1): 199-202. DOI: 10.1210/jcem.83.1.4516. |
| [33] | Müssig K., Kaltenbach S., Machicao F., Maser-Gluth C., Hartmann M. F., Wudy S. A., Schnauder G., Häring H-U., Seif F. J. and Gallwitz B. (2005). 17alpha-hydroxylase/17,20-lyase deficiency caused by a novel homozygous mutation (Y27Stop) in the cytochrome CYP17 gene. The Journal of Clinical Endocrinology and Metabolism. 90 (7). 4362-4365. DOI: 10.1210/jc.2005-0136. |
| [34] | Albaugh V. L., Pinzon-Guzman C. and Barbul A. (2017). Arginine Metabolism and Cancer. Journal of surgical oncology 115 (3). 273-280. |
| [35] | Razak M. A., Begum P. S., Viswanath B. and Rajagopal S. (2017). Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxidative Medicine and Cellular Longevity. 2017.8p. DOI: https://doi.org/10.1155/2017/1716701 |
| [36] | Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A. L., Kafri R., Kirschner M. W., Clish C. B. and Mootha V. K. (2012). Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation. Science. 336 (6084). 1040-1044. |
| [37] | Combs J. A. and DeNicola G. M. (2019). The Non-Essential Amino Acid Cysteine Becomes Essential for Tumor Proliferation and Survival. Cancers. 11 (5). 678. DOI: 10.3390/cancers11050678. |
| [38] | Mbaye F., Dem A., Fall M. and Sembène M. (2012). Biological evolution of tryptophan and phenylalanine in the occurrence of breast cancer in Senegalese women. International journal of medicine and medical sciences. 4 (4). 103-109. |
| [39] | Krall A. S., Xu S., Graeber T. G., Braas D. and Christofk H. R. (2016). Asparagine promotes cancer cell proliferation though use as an amino acid exchange factor. Nature Communications. 7. 11457. DOI: 10.1038/ncomms11457. |
| [40] | Sapino A., Bosco M., Cassoni P., Castellano I., Arisio R., Cserni G., Tos A. P. D., Fortunati N., Catalano M. G. and Bussolati G. (2006). Estrogen receptor- β is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Modern Pathology. 19 (4). 599-606. DOI: 10.1038/modpathol.3800574. |
| [41] | Bidgoli S. A., Ahmadi R. and Zavarhei M. D. (2010). Role of hormonal and environmental factors on early incidence of breast cancer in Iran. Science of The Total Environment. 48 (19). 4056-4061. |
| [42] | Vera-Sempere F. J. and Artes M. J. (1997). [Estrogen receptors and breast fibroadenoma with suspicious traits of malignancy]. Anales De Medicina Interna. 14 (7). 332-336. |
| [43] | Darbre P. D. (2006). Environmental oestrogens, cosmetics and breast cancer. Best Practice & Research Clinical Endocrinology & Metabolism. 20 (1). 121-143. |
| [44] | Van der Heiden E. Bechoux N., Muller M., Sergent T., Schneider Y-J., Larondelle Y., Maghuin-Rogister G. and Scippo M-L. (2009). Food flavonoid aryl hydrocarbon receptor-mediated agonistic/antagonistic/synergic activities in human and rat reporter gene assays. Analytica Chimica Acta. 637 (1). 337-345. |
| [45] | Wong P. S., Li W., Vogel C. F. and Matsumura F. (2009). Characterization of MCF mammary epithelial cells overexpressing the Arylhydrocarbon receptor (AhR). BMC Cancer. 9 (234). 1-15. DOI: 10.1186/1471-2407-9-234. |
APA Style
Gueye Rokhaya, Tendeng Jacques Noël, Kénémé Bineta, Sembene Pape Mbacké. (2020). Prevalence of Mutations of the MED12 and CYP17A1 Genes in Mammary Fibroadenomas in Senegalese Women. International Journal of Genetics and Genomics, 8(2), 66-77. https://doi.org/10.11648/j.ijgg.20200802.13
ACS Style
Gueye Rokhaya; Tendeng Jacques Noël; Kénémé Bineta; Sembene Pape Mbacké. Prevalence of Mutations of the MED12 and CYP17A1 Genes in Mammary Fibroadenomas in Senegalese Women. Int. J. Genet. Genomics 2020, 8(2), 66-77. doi: 10.11648/j.ijgg.20200802.13
AMA Style
Gueye Rokhaya, Tendeng Jacques Noël, Kénémé Bineta, Sembene Pape Mbacké. Prevalence of Mutations of the MED12 and CYP17A1 Genes in Mammary Fibroadenomas in Senegalese Women. Int J Genet Genomics. 2020;8(2):66-77. doi: 10.11648/j.ijgg.20200802.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijgg.20200802.13,
author = {Gueye Rokhaya and Tendeng Jacques Noël and Kénémé Bineta and Sembene Pape Mbacké},
title = {Prevalence of Mutations of the MED12 and CYP17A1 Genes in Mammary Fibroadenomas in Senegalese Women},
journal = {International Journal of Genetics and Genomics},
volume = {8},
number = {2},
pages = {66-77},
doi = {10.11648/j.ijgg.20200802.13},
url = {https://doi.org/10.11648/j.ijgg.20200802.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijgg.20200802.13},
abstract = {Fibroadenoma is the most common benign breast tumor in women under 30 years. This study aimed to contribute to the knowledge of the genetic factors involved in the occurrence and progression of mammary fibroadenomas. MED12 and CYP17A1 were sequenced in fibroadenomas and blood in 43 Senegalese women. The Alamut-visual software, which includes the pathogenicity prediction software SIFT, Polyphen2 and MutationTaster, was used to search for mutations. DnaSP version 5.10.01, MEGA version 7.0.14 and Arlequin version 3.5.1.3 were used to determine phylogenetic parameters including indices of genetic variability and diversity and genetic differentiation parameters. A deletion in the poly-A tail of MED12 was identified in our study population. An alteration of Methionine (M1) was observed on exon 1 of CYP17A1. Our results also show that most of the variants found on exon 2 of MED12 and exon 1 of CYP17A1 have the probability of causing the appearance of breast fibroadenomas according by the three pathogenicity prediction software. We found 23 new variants on the MED12 gene and 109 new variants on the CYP17A1 gene. The amino acid frequency distribution between blood and fibroadenomas shows a statistically significant difference in Glycine, Arginine and Valine for MED12 and Cysteine, Phenylalanine, Histidine, Asparagine, Arginine, Tryptophan and Tyrosine for CYP17A1. In addition the selection test shows that codon 20 of exon 1 of CYP17A1 which codes for Arginine (p.20Arg) is under positive selection in mammary fibroadenomas. Genetic differentiation parameters show a clear difference between blood and breast fibroadenomas. These results show for the first time the involvement of the CYP17A1 gene in breast fibroadenomas and confirm the involvement of MED12. Codon 20 of exon 1 of CYP17A1 being under positive selection could be used as a biomarker in breast fibroadenomas.},
year = {2020}
}
TY - JOUR T1 - Prevalence of Mutations of the MED12 and CYP17A1 Genes in Mammary Fibroadenomas in Senegalese Women AU - Gueye Rokhaya AU - Tendeng Jacques Noël AU - Kénémé Bineta AU - Sembene Pape Mbacké Y1 - 2020/03/23 PY - 2020 N1 - https://doi.org/10.11648/j.ijgg.20200802.13 DO - 10.11648/j.ijgg.20200802.13 T2 - International Journal of Genetics and Genomics JF - International Journal of Genetics and Genomics JO - International Journal of Genetics and Genomics SP - 66 EP - 77 PB - Science Publishing Group SN - 2376-7359 UR - https://doi.org/10.11648/j.ijgg.20200802.13 AB - Fibroadenoma is the most common benign breast tumor in women under 30 years. This study aimed to contribute to the knowledge of the genetic factors involved in the occurrence and progression of mammary fibroadenomas. MED12 and CYP17A1 were sequenced in fibroadenomas and blood in 43 Senegalese women. The Alamut-visual software, which includes the pathogenicity prediction software SIFT, Polyphen2 and MutationTaster, was used to search for mutations. DnaSP version 5.10.01, MEGA version 7.0.14 and Arlequin version 3.5.1.3 were used to determine phylogenetic parameters including indices of genetic variability and diversity and genetic differentiation parameters. A deletion in the poly-A tail of MED12 was identified in our study population. An alteration of Methionine (M1) was observed on exon 1 of CYP17A1. Our results also show that most of the variants found on exon 2 of MED12 and exon 1 of CYP17A1 have the probability of causing the appearance of breast fibroadenomas according by the three pathogenicity prediction software. We found 23 new variants on the MED12 gene and 109 new variants on the CYP17A1 gene. The amino acid frequency distribution between blood and fibroadenomas shows a statistically significant difference in Glycine, Arginine and Valine for MED12 and Cysteine, Phenylalanine, Histidine, Asparagine, Arginine, Tryptophan and Tyrosine for CYP17A1. In addition the selection test shows that codon 20 of exon 1 of CYP17A1 which codes for Arginine (p.20Arg) is under positive selection in mammary fibroadenomas. Genetic differentiation parameters show a clear difference between blood and breast fibroadenomas. These results show for the first time the involvement of the CYP17A1 gene in breast fibroadenomas and confirm the involvement of MED12. Codon 20 of exon 1 of CYP17A1 being under positive selection could be used as a biomarker in breast fibroadenomas. VL - 8 IS - 2 ER -
Information
Email: